Navigation Links
Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
Date:9/23/2008

rincipal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana- Farber/Harvard Cancer Center (DF/HCC), a designated comprehensive cancer center by the National Cancer Institute.

Forward-Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the ability of the HERmark assay to predict response to Herceptin or to significantly improve the information available to physicians, results of studies intended to demonstrate clinical utility of HERmark, and potential commercialization of the HERmark assay or other VeraTag assays. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the performance of our products, including HERmark; the risk that our VeraTag assays, including HERmark may not predict response to Herceptin or other therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional HERmark or VeraTag studies; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; actual market acceptance of our products for patient use and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and servi
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
3. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
4. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
6. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
7. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 ­ Caris Life Sciences®, ... of precision medicine, today announced it has appointed the ... center of excellence site in the Caris Centers of ... Levine Cancer Institute is one of the largest cancer ... 11,000 new cancer patients annually. Derek Raghavan , ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 WORMS, ... Grace & Co. (NYSE: GRA) announces that its ... manufacturing practice (GMP) certification from EXCiPACTâ„¢, an independent ... pharmaceutical excipients. , All three Grace ... pharmaceutical grade excipient silica gels have now received ...
(Date:5/26/2015)... California and HILDEN, Germany ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... of its QIAGEN Clinical Insight ® (QCI™) ... labs to interpret and report on genomic variants ... supported applications for the bioinformatics platform are in ...
(Date:5/26/2015)...  Alere Inc. (NYSE: ALR ) (the "Company") announced ... file its Quarterly Report on Form 10-Q for the three ... received a notice from the New York Stock Exchange (the ... NYSE,s continued listing requirements under the timely filing criteria established ... The reason for the delay relates to Company,s ...
Breaking Biology Technology:Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5
... , CRANBURY, N.J., Dec. 1 Palatin Technologies, Inc. ... U.S. Patent and Trademark Office has issued U.S. Patent ... claims in the issued patent cover a family of ... (NPRA), including PL-3994, Palatin,s lead heart failure drug candidate. ...
... , HUNTINGTON BEACH, ... molecular cancer diagnostics, announced today that,Palmetto GBA, California,s Part B ... MammaPrint is Agendia,s,FDA-cleared breast cancer recurrence test, which has been ... across the United States can now submit claims for the,MammaPrint ...
... , ... ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ... in the People,s Republic of China ("PRC"), today,announced that the ... ("MDK") to serve as its exclusive sales agent for the,Company,s ...
Cached Biology Technology:Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3
(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... the buzzword "nano" - cancer detection using nanoparticles and ... cancers is one of the most important parts of ... and determination,of the most appropriate treatment. And an essential ... there has been lymphatic spread. Current,methods include surgical removal ...
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... drugs that keep the HIV-virus infection from progressing to ... disturbances in some patients. The finding of a Mayo ... The Lancet. , In collaboration with colleagues from the ... University of Minnesota, Minneapolis, and University of Wisconsin, Madison, ...
Cached Biology News:Imaging Lymph Nodes with Nanoparticles 2GATA: a graphic alignment tool for comparative sequence analysis 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 3
Selective media for Salmonella...
... can be used as a fully functional, ... Software provides the means to record and ... These data can then be copied and ... Microsoft Excel or Lotus 123, or into ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Yeast Oligo Microarray Kit (V2), 2 ... simultaneously characterize expression of many thousands ... activity during important biological processes. Each ... 6,256 known ORFs from the S288C ...
Biology Products: